Product image of Nuvaring (Ethinylestradiol, Etonogestrel) supplied by GNH India

Nuvaring

Active Ingredient:
Ethinylestradiol, Etonogestrel
Origin:
EU

Nuvaring (Ethinylestradiol, Etonogestrel)

Etonogestrel/ethinyl estradiol, the active ingredient in NuvaRing, is a combined estrogen‑progestogen contraceptive presented as a vaginal ring releasing 0.015 mg/day ethinyl estradiol and 0.12 mg/day etonogestrel for vaginal use. It is indicated for prevention of pregnancy in women of reproductive age.

GNH India supplies NuvaRing as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

N.V. Organon

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

NuvaRing, a combined estrogen‑progestogen contraceptive, is used within the hormonal contraception pathway to prevent unintended pregnancy.

  • Prevention of pregnancy: provides reliable, reversible contraception for women of childbearing potential.
  • Family planning: enables controlled spacing of pregnancies when used as directed.
  • Contraceptive management: offers a user‑controlled, monthly method that does not require daily dosing.

How It Works

  • NuvaRing releases ethinyl estradiol and etonogestrel locally in the vagina, delivering steady plasma concentrations. Ethinyl estradiol provides estrogenic activity that stabilizes the endometrium, while etonogestrel, a progestogen, suppresses the hypothalamic‑pituitary‑ovarian axis, preventing the mid‑cycle surge of luteinising hormone and thereby inhibiting ovulation. The combined hormonal effect also thickens cervical mucus and alters the endometrial lining, creating multiple barriers to fertilisation and implantation.

Side Effects

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Breast tenderness: transient discomfort in the breasts.
  • Headache: occasional tension‑type headaches.
  • Mood changes: irritability or emotional fluctuations.
  • Vaginal irritation: local itching or discharge.
  • Spotting: irregular bleeding between cycles.

Serious or Rare Side Effects

  • Deep vein thrombosis: blood clot formation in deep veins.
  • Pulmonary embolism: clot migration to the lungs.
  • Stroke: cerebrovascular accident due to clot or hemorrhage.
  • Myocardial infarction: heart attack risk in susceptible individuals.
  • Severe allergic reaction: rash, swelling, or anaphylaxis.
  • Liver dysfunction: abnormal liver enzymes or jaundice.

Precautions & Warnings

Before using NuvaRing, consider the following precautions.

  • Smoking: avoid if over 35 years of age and a smoker, due to increased thrombotic risk.
  • History of thromboembolism: contraindicated in patients with prior deep vein thrombosis or pulmonary embolism.
  • Liver disease: use with caution in moderate to severe hepatic impairment.
  • Hypertension: monitor blood pressure regularly during use.
  • Breast cancer: contraindicated in current or past breast cancer patients.
  • Store at ambient temperature: keep in original packaging, protect from moisture and excessive heat.

Avoid Interactions

NuvaRing may interact with other medicines; review the following.

Major Interactions (Avoid)

  • Enzyme inducers (e.g., rifampin, phenytoin, carbamazepine): reduce contraceptive effectiveness.
  • Certain antiretrovirals (e.g., efavirenz): may lower hormone levels.
  • St. John’s wort: herbal inducer that can diminish efficacy.
  • Some antibiotics (e.g., rifampin): may increase hormone metabolism.
  • Anticonvulsants (e.g., phenobarbital): can decrease contraceptive reliability.

Moderate Interactions (Monitor Closely)

  • Other hormonal therapies (e.g., hormone replacement): may alter overall hormone exposure.
  • Antifungals (e.g., ketoconazole): can increase hormone concentrations.
  • SSRIs (e.g., fluoxetine): may affect bleeding patterns.
  • Diuretics (e.g., thiazides): may influence fluid balance and blood pressure.
  • Herbal supplements (e.g., ginseng): potential modest effect on hormone levels.

Frequently Asked Questions

NuvaRing is a prescription vaginal contraceptive ring that delivers a combined estrogen‑progestogen hormone regimen. It is used to prevent unintended pregnancy in women of reproductive age by providing a reversible, monthly method of hormonal birth control.

The ring continuously releases ethinyl estradiol and etonogestrel. Ethinyl estradiol stabilises the endometrium, while etonogestrel suppresses the luteinising hormone surge, preventing ovulation. Together they thicken cervical mucus and alter the uterine lining, creating multiple barriers to fertilisation and implantation.

The dosing regimen for NuvaRing is set by a qualified prescriber. Typically, a single ring is inserted vaginally and left in place for three weeks, followed by a one‑week ring‑free interval, after which a new ring is inserted.

NuvaRing is contraindicated in pregnancy (Category X) and must not be used by women who are pregnant or suspect they might be. It is also not recommended during breastfeeding because hormonal exposure may affect milk production and infant exposure.

To order NuvaRing, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with daily oral contraceptive pills, NuvaRing offers a once‑monthly dosing schedule, which can improve adherence. Unlike injectable progestogen-only methods, the ring provides both estrogen and progestogen, giving a more balanced hormonal profile similar to combined oral pills but without daily administration.

NuvaRing should be stored at ambient temperature, below 25 °C, in its original sealed packaging. Keep the ring away from direct sunlight, moisture and excessive heat to maintain hormone stability throughout its shelf life.

A healthcare professional or the user inserts the flexible vaginal ring into the upper vagina, where it remains for three weeks. After a one‑week break, a new ring is inserted. The ring should be positioned so that it does not cause discomfort and can be removed easily for disposal.

Serious risks include venous thromboembolism (deep vein thrombosis, pulmonary embolism), arterial events such as stroke or myocardial infarction, severe allergic reactions, and liver dysfunction. Women with a history of clotting disorders, cardiovascular disease, or certain cancers should avoid using NuvaRing.

NuvaRing is contraindicated in women who are pregnant, have a known or suspected breast cancer, have active liver disease, have uncontrolled hypertension, are smokers over 35 years old, or have a history of thromboembolic disorders. It should also be avoided in individuals with known hypersensitivity to any component of the ring.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ethinylestradiol, Etonogestrel

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT